As a result, multiple Phase II clinical trials were initiated to test the efficacy of several anti-IGF-1R antibody candidates, including IMC-A12 (cixutumumab, NCT00684983, NCT00699491), MK-0646 (dalotuzumab, NCT01605396, NCT00903006), AMG-479 (ganitumab, NCT00626106), and CP-751,871 (figitumumab, NCT00372996, NCT00976508), as a component of multidrug treatment regimens in both HER2+ and hormone receptor (HR) positive, HER2− breast cancer. The gene discussed is ERBB2; the disease is breast cancer.